This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 May 2012

Bayer Yakuhin & Santen Enter Agreement for Eylea Injections

Bayer Yakuhin and Santen will team up to promote Eylea in Japan.

Bayer's Japanese subsidiary, Bayer Yakuhin, has announced a new co-promotion agreement with Santen Pharmaceutical for injectable Eylea (aflibercept) in Japan.


Eylea is designed to treat neovascular age-related macular degeneration (wet AMD) and an application for marketing authorisation has already been submitted to the ministry of health, labour and welfare for this indication.


Sebastian Guth, president & chief executive officer of Bayer Yakuhin, said: "With this agreement and upon marketing authorisation, a newly formed Bayer Yakuhin ophthalmology field force and Santen, the leading ophthalmology company in Japan, will promote Eylea."


Mr Guth claime

Related News